Last 48 quarters of trend data · Energy · Oil & Gas Equipment & Services
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
EV/EBITDA has expanded 32.7% YoY to 35.0x, reflecting rising market expectations or slowing EBITDA growth.
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | 18.71 | — | 26.72 | 10.30 | 13.09 | — | 27.05 | 18.53 | 26.70 | 63.26 | 88.30 | 31.59 | 12.11 |
| — | — | -1.2% | -44.4% | -51.0% | — | -69.4% | -41.3% | +120.5% | -42.6% | +143.9% | +50.0% | -63.3% | |
| P/S Ratio | 1.11 | 1.59 | 1.35 | 1.08 | 1.05 | 1.42 | 1.60 | 1.65 | 1.85 | 1.57 | 1.64 | 2.28 | 2.16 |
| — | +12.0% | -15.7% | -34.4% | -43.3% | -9.7% | -2.3% | -27.7% | -14.1% | -22.9% | -12.0% | +81.3% | +11.8% | |
| P/B Ratio | 2.11 | 2.81 | 2.66 | 2.10 | 2.05 | 2.70 | 3.21 | 3.46 | 3.94 | 3.43 | 3.65 | 4.98 | 5.03 |
| — | +4.0% | -17.0% | -39.3% | -48.1% | -21.2% | -12.2% | -30.6% | -21.6% | -34.4% | -27.2% | +44.1% | +88.6% | |
| P/FCF | 25.93 | 48.77 | 43.22 | 26.59 | 13.57 | 56.89 | 12.73 | 21.36 | 16.96 | 82.30 | 12.46 | — | 43.12 |
| — | -14.3% | +239.4% | +24.5% | -20.0% | -30.9% | +2.2% | — | -60.7% | — | -41.3% | — | — | |
| EV / EBITDA | 12.11 | 35.04 | 12.82 | 7.37 | 7.66 | 26.40 | 13.85 | 11.28 | 14.57 | 20.38 | 14.09 | 18.21 | 14.38 |
| — | +32.7% | -7.4% | -34.6% | -47.4% | +29.5% | -1.7% | -38.0% | +1.3% | -32.2% | -4.0% | +60.1% | -20.7% | |
| EV / EBIT | 15.75 | 104.93 | 16.08 | 8.64 | 11.36 | 48.62 | 17.43 | 13.38 | 18.00 | 29.52 | 17.45 | 23.09 | 17.92 |
| — | +115.8% | -7.7% | -35.4% | -36.9% | +64.7% | -0.2% | -42.1% | +0.4% | -39.5% | -5.7% | +58.0% | -21.2% |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
Core Laboratories N.V.'s operating margin was 1.5% in Q1 2026, down 8.9 pp QoQ and down 2.0 pp YoY. This marks the 3rd consecutive quarter of margin compression, signaling a persistent pressure on profitability that investors should monitor. The trailing four-quarter average of 9.8% exceeds the current quarter, suggesting the latest result may reflect seasonal weakness or a one-off headwind.
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 17.9% | 16.2% | 18.1% | 19.3% | 17.5% | 16.5% | 15.0% | 17.8% | 18.3% | 16.4% | 20.8% | 19.8% | 21.6% |
| — | -1.9% | +21.0% | +8.7% | -4.3% | +0.9% | -28.0% | -10.1% | -15.2% | -7.8% | +12.2% | +9.0% | +13.7% | |
| Operating Margin | 9.3% | 1.5% | 10.4% | 15.6% | 11.7% | 3.6% | 11.0% | 14.7% | 12.3% | 6.6% | 11.4% | 11.7% | 14.8% |
| — | -56.7% | -4.8% | +5.6% | -4.2% | -45.9% | -3.6% | +25.9% | -17.1% | +30.9% | -7.1% | +0.7% | +53.4% | |
| Net Margin | 6.0% | -0.6% | 5.1% | 10.6% | 8.2% | -0.1% | 5.7% | 8.7% | 6.9% | 2.5% | 1.7% | 7.4% | 17.9% |
| — | -419.9% | -10.6% | +21.1% | +18.1% | -105.0% | +234.0% | +18.3% | -61.3% | +34.4% | -67.6% | +23.6% | +205.7% |
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 11.8% | -0.3% | 2.5% | 5.2% | 4.0% | -0.1% | 2.9% | 4.7% | 3.7% | 1.4% | 1.0% | 4.1% | 10.9% |
| — | -377.2% | -11.7% | +11.8% | +8.0% | -104.3% | +200.7% | +13.5% | -65.7% | +13.0% | -73.6% | +46.2% | +298.0% | |
| ROA | 5.4% | -0.1% | 1.2% | 2.4% | 1.8% | -0.0% | 1.2% | 2.0% | 1.5% | 0.5% | 0.4% | 1.6% | 3.8% |
| — | -410.3% | -4.1% | +21.7% | +17.0% | -104.8% | +233.2% | +26.5% | -60.1% | +35.4% | -68.3% | +37.5% | +264.9% | |
| ROIC | 8.3% | 0.4% | 2.5% | 3.8% | 2.8% | 0.8% | 2.5% | 3.5% | 2.8% | 1.5% | 2.5% | 2.5% | 3.3% |
| — | -52.8% | -2.0% | +8.9% | -0.8% | -46.7% | -0.2% | +36.7% | -16.9% | +24.6% | -14.1% | +13.3% | +86.2% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
Core Laboratories N.V.'s Debt/EBITDA ratio is 7.3x, down from 11.4x last quarter — elevated, raising questions about debt serviceability. The current ratio has weakened 7.2% YoY to 2.05x, tightening the short-term liquidity position.
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.74 | 0.15 | 0.74 | 0.60 | 0.67 | 0.69 | 0.70 | 0.76 | 0.82 | 0.89 | 0.94 | 1.00 | 1.07 |
| — | -78.4% | +5.5% | -20.8% | -18.5% | -22.4% | -25.4% | -23.6% | -23.7% | -23.9% | -20.4% | -22.7% | +54.0% | |
| Debt / EBITDA | 3.25 | 7.31 | 11.39 | 6.81 | 7.87 | 22.13 | 10.10 | 8.31 | 10.18 | 17.10 | 11.67 | 12.29 | 10.32 |
| — | -67.0% | +12.8% | -18.0% | -22.6% | +29.4% | -13.5% | -32.4% | -1.4% | -23.5% | +3.3% | -2.1% | -32.4% | |
| Current Ratio | 2.07 | 2.05 | 2.07 | 2.37 | 2.27 | 2.21 | 2.32 | 2.48 | 2.39 | 2.68 | 2.53 | 2.71 | 2.45 |
| — | -7.2% | -10.6% | -4.3% | -5.2% | -17.7% | -8.3% | -8.7% | -2.5% | +12.4% | +23.4% | +21.4% | +65.8% | |
| Quick Ratio | 1.57 | 1.50 | 1.57 | 1.76 | 1.70 | 1.64 | 1.71 | 1.79 | 1.68 | 1.85 | 1.72 | 1.82 | 1.71 |
| — | -8.6% | -8.6% | -1.5% | +1.3% | -11.7% | -0.3% | -1.9% | -1.9% | +10.3% | +17.2% | +13.3% | +50.3% | |
| Interest Coverage | 4.95 | 0.65 | 7.60 | 7.90 | 5.64 | 1.70 | 5.39 | 6.37 | 4.99 | 2.50 | 4.12 | 4.66 | 5.66 |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 48 years · Updated daily
Total return calculator · dividends reinvested
Calculate ReturnsDollar cost averaging vs lump sum · see how regular investing compounds over time
Run the NumbersDCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare business quality, growth, and profitability against top sector peers.
Compare NowQuick answers to the most common questions about buying CLB stock.
Core Laboratories N.V.'s current P/E is 18.7x. The average P/E over the last 3 quarters is 16.7x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Core Laboratories N.V.'s current operating margin is 9.3%. Margins have been compressing over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Core Laboratories N.V.'s business trajectory between earnings reports.